Adage Capital Partners GP L.L.C. Sells 54,743 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Adage Capital Partners GP L.L.C. decreased its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 7.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 713,200 shares of the biotechnology company's stock after selling 54,743 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 1.26% of Astria Therapeutics worth $6,376,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in ATXS. Rhumbline Advisers boosted its stake in Astria Therapeutics by 2.3% in the 4th quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock worth $556,000 after purchasing an additional 1,381 shares during the period. Hsbc Holdings PLC lifted its holdings in shares of Astria Therapeutics by 9.0% in the fourth quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company's stock worth $170,000 after buying an additional 1,587 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Astria Therapeutics by 7.6% in the fourth quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 2,222 shares during the period. Tower Research Capital LLC TRC grew its stake in Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 2,766 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Astria Therapeutics by 19.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company's stock worth $159,000 after acquiring an additional 2,878 shares during the period. Hedge funds and other institutional investors own 98.98% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Wedbush restated an "outperform" rating and issued a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 29th. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Finally, JMP Securities initiated coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an "outperform" rating and a $26.00 target price for the company. Five analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Stock Up 3.9 %

Shares of NASDAQ ATXS traded up $0.20 during trading hours on Friday, reaching $5.36. 408,704 shares of the stock traded hands, compared to its average volume of 363,361. The company's 50-day simple moving average is $5.40 and its two-hundred day simple moving average is $7.85. The company has a market capitalization of $302.49 million, a P/E ratio of -2.56 and a beta of 0.45. Astria Therapeutics, Inc. has a 52-week low of $3.56 and a 52-week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. As a group, sell-side analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.